HOWL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Werewolf Therapeutics Inc (HOWL) is not a good buy for a beginner investor with a long-term strategy at this time. The stock faces significant challenges, including cash constraints, lack of positive financial performance, and a negative sentiment from analysts. While the technical indicators are neutral, there are no strong positive catalysts to justify an investment.
The MACD is slightly positive at 0.0105, indicating weak bullish momentum, but it is contracting. RSI is neutral at 49.056, and moving averages are converging, showing no clear trend. Support and resistance levels suggest limited upside potential with a pivot at 0.666 and resistance at 0.725.
The company's pipeline shows some clinical activity and a clean safety profile for WTX-124 and WTX-330.
Hedge funds are selling heavily, with a 755.50% increase in selling activity. Analysts have downgraded the stock, citing cash constraints and uncertain timing for partnerships or funding. Financial performance is poor, with no revenue growth, a significant net loss, and declining EPS. No recent news or influential trading activity to support the stock.
In Q3 2025, revenue remained at $0 with no growth. Net income dropped to -$16.37 million, down 1.82% YoY. EPS fell to -0.36, down 5.26% YoY. Gross margin dropped to 0, indicating no profitability.
Analysts have a negative outlook on the stock. H.C. Wainwright lowered the price target to $4 from $10 but maintained a Buy rating, citing progress in the pipeline. Wedbush downgraded the stock to Neutral from Outperform, reducing the price target to $1 from $3, citing cash constraints. Citizens also downgraded the stock to Market Perform due to uncertain timing for partnerships or funding.
